Basal Insulin
Join Trial Testing Once-Weekly Insulin for Type 1 Diabetes
This clinical trial is comparing the safety and effectiveness of once-weekly insulin icodec to daily insulin glargine for people with type 1 diabetes.
Lilly’s Once-Weekly Insulin Equally Effective as Daily Insulin for Improving A1C
Lilly’s efsitora alfa shows promise as a once-weekly insulin, matching daily basal insulin in type 2 diabetes for efficacy and safety, potentially simplifying diabetes management.
Sanofi to Build New State-of-the-Art Insulin Plant
August 5, 2024
6 Benefits of Combining Insulin and GLP-1 Drugs
Basal insulin and GLP-1 combination drugs like Xultophy and Soliqua enhance diabetes management while reducing side effects.
Long-Acting Basaglar and the New Era of “Biosimilar” Insulin
What you need to know about the new insulin, its cost, dosing, and beyond!
Xultophy Beats Out Lantus in Major Clinical Trial
One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand new phase 3 clinical trial data comparing Xultophy (a GLP-1 agonist/long acting insulin combination taken as a single injection) to Lantus (a long acting insulin) for the treatment of type 2 diabetes. The results of the 26-week study were very impressive...